"East to West" cell therapy subsidiary, AdCella, has completed its first Joint Development Committee Meeting with Shanghai Cell Therapy Group. The meeting identified important opportunities to accelerate development timelines and reduce regulatory risk.

AdAlta CEO and Managing Director, Tim Oldham said:

“This first JDC meeting is an important milestone for the BZDS1901 program, bringing together SHcell’s development experience with AdCella’s Australian clinical and manufacturing plans.The potential to bring manufacturing technology transfer forward significantly strengthens our regulatory and clinical pathway, while the refined FDA engagement strategy is expected to reduce development risk.”